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ABSTRACT
Autosomal recessive osteopetrosis (OP) is a rare, lethal disorder in which osteoclasts are absent or nonfunc-
tional, resulting in a bone marrow cavity insufficient to support hematopoiesis. Because osteoclasts are derived
from hematopoietic precursors, allogeneic hematopoietic cell transplantation can cure the bony manifestations
of the disorder. However, high rates of graft failure have been observed in this population. It is not possible to
harvest bone marrow from these patients for reinfusion should graft failure be observed. We report that 8 of
10 patients with OP had high numbers of circulating CD34 cells (3%  0.9%). This increased proportion of
peripheral CD34 cells made it possible to harvest 2  106 CD34 cells per kilogram with a total volume of
blood ranging from 8.3 to 83.7 mL (1.3-11.6 mL/kg). In addition, colony-forming assays documented signif-
icantly more colony-forming unit–granulocyte-macrophage and burst-forming unit–erythroid in the blood of
osteopetrotic patients compared with controls; the numbers of colony-forming units approximated those found
in control marrow. We conclude that OP patients with high levels of circulating CD34 are candidates for
peripheral blood autologous harvest by limited exchange transfusion. These cells are then available for
reinfusion should graft failure be observed in patients for whom retransplantation is impractical.
© 2005 American Society for Blood and Marrow Transplantation
KEY WORDS
Osteopetrosis ● Leukoerythroblastic ● Peripheral blood stem cells ● Osteoclasts
t
c
u
[
o
r
f
o
t
mNTRODUCTION
Malignant infantile osteopetrosis (MIOP) is a rare
enetic disease characterized by generalized osteoscle-
osis, which results from a functional or numeric de-
ciency of osteoclasts [1]. Major consequences are
usceptibility to fractures and nerve compression due
o failure of remodeling of the skull base; this results
n optic, auditory, and facial nerve compression and
ydrocephalus. Obliteration of marrow cavities results
n extramedullary hemopoiesis, resulting in hepato-
plenomegaly and, frequently, progression to life- p
B&MThreatening pancytopenia. There is also increased sus-
eptibility to infection in some patients because of an
nexplained defect of neutrophil superoxide function
2]. This combination of problems results in the death
f 70% of affected children by the age of 6 years [3].
Although beneﬁcial effects have been reported in
esponse to a variety of drugs (most notably -inter-
eron [4]), stem cell transplantation (SCT) remains the
nly curative therapy and forms the cornerstone of
reatment. After successful engraftment, children nor-
alize their bone density (Figure 1) and hematologic
arameters and have stabilization or prevention of
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1ranial nerve damage and hydrocephalus. Results are
xcellent after matched sibling allogeneic grafts; 73%
f patients are alive and disease free at 5 years after
ransplantation [5].
Unfortunately, results are much poorer after non-
dentical bone marrow (BM) transplantation. For
xample, Gerritsen et al. [6] reported nonengraftment
n 15 of 45 patients who received non–HLA-identical
ransplants. In some cases, engraftment can be
chieved by proceeding immediately to a second graft
rom the same or an alternative donor after immune
econditioning with agents such as OKT3 and high-
ose steroids. However, this may be contraindicated
y severe toxicity, such as veno-occlusive disease, or
nfection. For these high-risk patients, the usual man-
gement would be to attempt rescue of the patient by
einfusing autologous “backup” marrow harvested be-
ore BM transplantation. However, this is not possible
n MIOP, in which densely sclerotic bones and min-
mal BM cavities preclude autologous harvest. As a
onsequence, primary rejection may result in pro-
onged aplasia and infective death before count recov-
ry.
It has long been recognized that immature my-
loid and erythroid precursors circulate in increased
umbers in patients with MIOP, producing a leuko-
igure 1. Resolution of osteosclerosis after bone marrow transplan-
ation. Before bone marrow transplantation (left), the leg bones were
rossly sclerotic and showed ﬂaring of the distal diaphyses (Ehrlen-
eyer ﬂask deformity). By 10 months after bone marrow transplanta-
ion (right), there was a marked reduction in bone density and an
mprovement in bone modeling.rythroblastic blood picture [7,8]. This is thought to s
16e a consequence of the reduced space in the BM
avities (myelophthisis). In 1995, we began to inves-
igate spontaneous peripheral blood stem cell (PBSC)
umbers in presenting osteopetrotic patients, reason-
ng that, if they were markedly increased, this could
rovide an alternative source of cells for rescue in the
vent of failed engraftment. We present data on 10
onsecutive patients with characteristic presentations
f MIOP. We report both unstimulated PBSC counts
nd colony-forming unit (CFU) assay results, with
ppropriate controls. Details are also reported on 2
atients who received an autologous reinfusion after
ailed engraftment.
A further advantage of our work has been to fa-
ilitate studies of osteoclast culture from children with
oth typical and atypical presentations of MIOP
9,10]. In time, this approach may allow better classi-
cation of the disease and correlation of the clinical
anifestations of the disease with speciﬁc genetic de-
ects. It may also allow antenatal diagnosis for families
n whom the gene disorder cannot be characterized.
ATERIALS AND METHODS
atients
Patients were 10 consecutive referrals of infants
ith MIOP to the BM transplantation unit of the
oyal Hospital for Children, Bristol, and the Depart-
ent of Pediatrics, University of Minnesota. All had
ypical presentations of severe MIOP, including neo-
atal hypocalcemic convulsions; nystagmus or blind-
ess; abdominal swelling secondary to hepatospleno-
egaly; thrombocytopenia, anemia, or both; and an
ncidental ﬁnding of osteosclerosis on a failure-to-
hrive screen. Exceptions were patients 1 and 5, dis-
ussed below. Two children were siblings and, for
larity, are presented as subjects 3A and 3B. Full blood
ounts at presentation and corresponding patient ages
re shown in Table 1. Peripheral blood (PB) speci-
ens were obtained for analysis by ﬂow cytometry
nd clonogenic assays with informed consent.
It is likely that patient 1 had an intermediate form
f the disease that is consistent with a longer life
xpectancy [11]. She was the oldest child, by a consider-
ble margin, to undergo transplantation (at 5 years
months). Even though she had neonatal hypocalce-
ia [12], osteopetrosis (OP) was not diagnosed until 9
onths of age, when she lost all vision. Subsequent
rowth was poor (height less than the 0.4th percen-
ile), and frequent fractures occurred with minimal
rauma. However, on referral for transplantation, the
atient had minimal hepatomegaly, no splenomegaly,
nd a well-preserved blood count—atypical ﬁndings
or severe MIOP.
Patient 5, an Omani of Bedouin ancestry, pre-
ented with early severe anemia, thrombocytopenia,
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Stem Cell Transplantation for Malignant Infantile Osteopetrosis
Bnd gum hypertrophy. Irritability was ascribed to mul-
iple fractures, but spasticity developed during the
ourse of transplantation, suggesting neuronopathic
P (a variant in which osteosclerosis is part of a
eneralized neurometabolic disease; when recognized
arly, this form of OP is not a candidate for transplan-
ation because the progression of neurologic disease is
naffected by SCT) [13]. During subsequent SCT,
blative chemotherapy was poorly tolerated, and se-
ere veno-occlusive disease ensued that resulted in
eath at day 12 after SCT. At postmortem examina-
ion, neuronal eosinophilic inclusions were identiﬁed,
hus conﬁrming the diagnosis of neuronopathic OP.
rogenitor Assays
Mononuclear cells (MNCs) were separated by
icoll-Hypaque density gradient centrifugation (Gibco;
nvitrogen Corporation, Paisley, UK), and residual red
lood cells were lysed with an ammonium chloride
uffer. Assays were performed on fresh MNC prepara-
ions from 3 patients (patients 2, 4, and 6) and on cryo-
reserved MNCs from the remaining 7 patients. The
ontent of CFU–granulocyte-macrophage (CFU-GM)
nd burst-forming unit–erythroid (BFU-E) progenitors
as evaluated in standard short-term methylcellulose
ssays [14]. Cultures were initiated in triplicate at 104
o 106 cells per milliliter and supplemented with
rythropoietin (3 IU/mL), interleukin-3 (10 ng/mL),
ranulocyte-macrophage colony-stimulating factor
10 ng/mL), and stem cell factor (50 ng/mL; all R&D
ystems, Europe, Ltd., Abingdon, UK). Plates were
ncubated at 37°C in 5% CO2 for 14 days, and colo-
ies were then counted by using an inverted micro-
cope. The controls included 2 PB samples from
ealthy volunteers and 4 normal BM samples from
olunteer unrelated donors, collected with consent on
he day of allogeneic transplantation.
able 1. Osteopetrosis Patient Data: Full Blood Counts and Patient De
Variable 1 2 3A
ge at first FBC 5 y 2 mo 1 wk 4.5 mo
emoglobin (g/dL) 9.7 19.6 12.1
BC ( 109/L) 14.5 19.9 28.2
Neutrophils 50 62 38
Lymphocytes 48 30 38
Monocytes 2 8 11
Eosinophils 0 NR 0
Metamyelocytes 0 NR 4
Myelocytes 0 NR 6
Basophils 0 NR 3
ucleated RBC (per 100 WBC) 1 NR 7
latelets ( 109/L) 199 300* 151
Patient 2 demonstrates how rapidly thrombocytopenia can evolve, b
just 1 month later.
BC indicates full blood count; WBC, white blood cell; RBC, redFibroblast colony-forming assays (CFU-F) assays b
B&MTere performed in parallel on PB samples from pa-
ients 1, 6, 7, and 8 and BM samples from 10 healthy
dult volunteer unrelated donors. Red blood cells
ere lysed with ammonium chloride and resuspended
n MesenCult medium (StemCell Technologies Inc.,
ancouver, Canada) at concentrations ranging from
to 5  105/mL (MIOP samples) or 0.5 to 2 
05/mL (normal BM) in 25-mL tissue culture ﬂasks
Farenheit Lab Supplies, Milton Keynes, UK). After
ncubation at 37°C for 14 days, medium was removed,
nd adherent cells were ﬁxed, stained with Giemsa
olution (BDH, Poole, UK), and counted.
resence of Stimulatory Cytokines
To exclude the presence of increased levels of
timulatory cytokines in MIOP serum contributing to
igh PBSC counts, 100 L of patient serum from
atient 2 (taken just before the commencement of
onditioning therapy) was added to a set of clonogenic
ssay plates initiated with 104 normal BM cells. Nor-
al human AB serum (100 L) was also added in
riplicate as a control. The cultures were incubated
nd scored as described previously.
mmunophenotypic Analysis
Phenotypic analysis was performed by ﬂow cytom-
try on the Coulter EPICS XL-MCL (Beckman
oulter, High Wycombe, UK) as described previ-
usly [15]. The percentage of CD45 MNCs (ﬂuo-
escein isothiocyanate–labeled anti-CD45; Sigma Di-
gnostics, St. Louis, MO) that expressed the CD34
ntigen (phycoerythrin-labeled anti-CD34; BD Bio-
ciences, Oxford, UK) was determined by assessing a
inimum of 50 000 gated events.
utologous PBSC Harvests
PBSC backups were obtained in 7 patients either
the Time of CD34 Cell Counts and Progenitor Assays
Patient No.
4 5 6 7 8 9
k 5 mo 3 mo 7.5 mo 7 mo 11 mo 2 y 1 mo
.5 9.7 10.1 10.1 8.4 9.9 30.5
.2 12.6 21.9 23.1 20.1 30.7 7.4
23 50 32 24 31 46
63 27 58 71 50 43
2 20 1 5 12 5
6 2 2 0 2 0
NR NR 5 0 0 2
5 NR 1 0 5 3
0 NR 0 0 0 1
16 NR 2 13 18 36
90 30 189 130 60 46
a pretransplantation platelet count of 22  109/L was documented
cell; NR, not reported.tails at
3B
1 w
21
35
51
30
9
0
NR
NR
NR
NR
122
ecausey removal of a sufﬁcient volume of blood (if the
117
p
c
c
w
a
q
p
t
a
w
o
v
1
p
s
f
r
R
P
i
T
1
4
c
5
s
t
t
d
t
t
1
p
1
a
h
t
t
a
e
c
f
w
t
c
s
a
T
2
3
3
4
6
7
8
9
M
C
W
T
O
2
3
3
4
6
7
8
9
O
C
C
T
W
C. G. Steward et al.
1redicted volume to achieve a yield of 2 106 CD34
ells per kilogram was 7 mL/kg) or by limited ex-
hange. Exchanges were performed against fresh
hole blood (collected in citrate phosphate dextrose
nd transfused through a blood warmer) in 10-mL ali-
uots with the aim of exchanging a maximum of 100 mL
er 15-minute period. Serum calcium was checked at
he mid and end points of the procedure, and temper-
ture, pulse, respiration rate, and blood temperature
ere recorded at the same times. No adverse events
ccurred during any procedure.
PB CD34 cell counts were low just before har-
est (1.2 and 4.34  107/L, respectively) in patients
and 5, children with intermediate and neurono-
athic forms of OP, respectively. Granulocyte colony-
timulating factor (G-CSF; 10 g/kg/day) was there-
ore administered to these children for 1 and 5 days,
espectively, before exchange transfusion.
ESULTS
rogenitor Cell Counts
The results of CD34 cell assays and CFU assays
n PB samples from MIOP patients are shown in
able 2, excluding results from the 2 patients (patients
and 5) with atypical OP. When ﬁrst investigated at
years, patient 1 had a CD34 cell count of 0.1% and
orrespondingly low progenitor assay results. Patient
had a CD34 cell count of 40.2  107/L when ﬁrst
tudied at 2 months of age, but this decreased spon-
aneously to 4.3  107/L just 2 weeks later without
herapy. Progenitor studies in this patient were con-
ucted on a sample taken at autologous PBSC collection
aken after 5 days of G-CSF stimulation. By this stage,
he absolute CD34 cell count had increased from 4.3
07/L to 23.0  107/L, and the CFU-GM and BFU-E
able 2. CD34 Content and Progenitor Counts of Peripheral Blood Sa
Patient No.
Age at Time of
CD34 Assay
(mo)
WBC at Time
of CD34 Assay
( 109/L)
Degree
Hepatomegal
Splenomegaly
2.5 13.1 L 2.5, S
A 5 19.3 L 3.5, S
B 1 14.3 No hepatosple
6.5 12.3 L 1, S
7.5 15.8 L 2, S
6 16.6 L 4, S
13 9.7 L.6, S 2
26 23.1 L 4, S.4
ean  SD 15.5  4
D34 content is expressed as a percentage of mononuclear cells. Pat
affected viability in the sample from patient 3A (assessed by tr
progenitor cell content between siblings. The volume of PB requ
kilogram of recipient weight was estimated; where a harvest was
The amount of blood required for a harvest of 2  106 CD34
BC indicates white blood cells.recursor frequencies were 202  10 and 621  31 per
1805 cells, respectively. The BFU-E from patient 5 were
lso unusually large and well hemoglobinized.
One patient (patient 3A), the sister of patient 3B,
ad a 10-fold lower frequency of progenitors. Ex-
ended storage of the sample may have contributed to
his discrepancy (after thawing, the contents of the
mpoule showed only 25% viability by trypan blue
xclusion), although this seems unlikely to be the sole
ause. The relatively low progenitor potential of cells
rom patient 9 is unexplained, although it was note-
orthy that most CFU-GM colonies derived from
his child were particularly large (up to 106 cells per
olony).
Assay results for normal PB and BM samples are
hown in Table 3. As expected, the CD34 percent-
ges of normal (unstimulated) blood were very low,
om MIOP Patients
d
)
Absolute CD34 
107/L (% of MNC)
Total Blood
Collected (mL) for
2  106 CD34/kg
Required
Blood Volume
(mL/kg)
83.8 (6.40%) 9.5 2.1
156.0 (8.10%) 8.3 1.3
aly 22.9 (1.60%) 35.8 8.7
36.9 (3.00%) 35.2 5.4
43.4 (2.8%) 23.5 4.5
17.3 (1.04%) 83.2 11.6
31.0 (3.20%) 42.6 6.5
26.3 (1.14%) 83.7 7.6
52  17 (3  0.9%) 40  29 6.0  3.4
and 3B were siblings. Defects in the freeze/thaw process may have
lue exclusion as 25%), thus explaining the marked differences in
produce an autologous harvest containing 2  106 CD34 cells per
ed, the actual volume required to achieve this yield is also shown.
r kilogram is presented on a per-kilogram basis.
able 3. Progenitor Assays from Normal PB and BM Samples and
P Patients
Patient No.
CFU-GM/105
Cells
BFU-E/105
Cells
780  75 460  10
A 19  3 12  2
B 310  60 110  7
750  38 227  9
555  45 290  90
660  10 360  80
157  9 145  20
65  7 39  4
P patients (mean  SD) 412  312 205  158
ontrol PBMC (n  2) 0.7  0.15 1.8  0.2
ontrol BM (n  8) 341  150 277  166
he CFU-GM and BFU-E progenitor cell content in peripheral
blood from OP patients was comparable to that of marrow from
volunteer unrelated adult bone marrow donors but was signiﬁ-
cantly different from assays from normal adult PB (P  .02).
BC indicates white blood cells; PBMC, peripheral blood mono-mples fr
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Stem Cell Transplantation for Malignant Infantile Osteopetrosis
Bnd their ability to produce progenitors was limited.
hese differences contrasted with those of the MIOP
B, for which the CD34 cell percentages ranged
rom 1.04% to 8.1% in the remaining 8 children, a
esult very similar to that obtained from normal BM
1.5%-3.2% CD34 cells after an MNC enrichment
rocess). The proliferative capacity of MIOP PB was
omparable to that of normal BM. The addition of
erum taken at the time of exchange transfusion from
n MIOP patient (patient 2) to one of the normal BM
amples neither enhanced nor inhibited progenitor
roliferation (data not shown). This suggests that the
igh frequency of myeloid and erythroid colonies in
IOP PB was not due to the presence of a stimulatory
ytokine in the serum, although these tests were not
epeated with serum from other patients.
CFU-F were generated from all normal BM sam-
les. Their frequency showed the expected linear rela-
ionship with number of cells plated: 27  3 colonies
ere formed when cultured at 105 cells per milliliter. Of
he MIOP samples, 2 (patients 7 and 8) showed dis-
ersed ﬁbroblasts, but none grew CFU-F colonies, thus
mplying that these cells lack mesenchymal stem cells.
utologous Harvest Potential and Reinfusions
The estimated and actual PB harvest requirements
o provide a potential backup of stem cells (2  106
D34/kg body weight) before BM transplantation
ere calculated (Table 2). For the 8 patients with
ypical MIOP (including patient 5 after G-CSF stim-
lation), this ranged from only 8.3 to 83.7 mL, equat-
ng to a CFU-GM content of 0.5 to 126  104/kg,
espectively. In patient 1, the calculated volume was
82 mL, although only 300 mL was taken at exchange
ransfusion.
Autologous PB backups were returned to 2 chil-
ren (patients 1 and 4). Both had undergone high-
ose haploidentical parental SCT after conditioning
herapy with busulphan, cyclophosphamide, and anti-
hymocyte globulin, and both experienced primary
raft rejection conﬁrmed by HLA typing of residual
hite blood cells. The CD34 cell content in re-
urned MNCs was 1.26 and 2.35 106/kg for patients
and 4, respectively.
In patient 1, the transplantation had been compli-
ated by acute respiratory obstruction requiring ur-
ent tracheostomy (on a background of long-standing
pper respiratory tract obstruction exacerbated by
ucositis), adenovirus infection, and early cytomega-
ovirus reactivation. After transient donor neutrophil
ecovery, the lymphocyte count increased, and neu-
rophils decreased to 0; the lymphocyte population
as shown by microsatellite polymerase chain reac-
ion to be exclusively of recipient origin, and this
uggested graft rejection. Because of the patient’s crit-
cal clinical situation, autologous PB was reinfused on w
B&MTay 15 after transplantation (the lymphocyte count at
his stage was 0.7, and neutrophils were 0  109/L).
eutrophils were sustained 0.5  109/L on 3 con-
ecutive days by 17 days after reinfusion. Recovery was
lower in patient 4, who received autologous reinfu-
ion on day 19 after SCT (the white blood cell count
as 0 at infusion). Although neutrophils of 0.3 
09/L were achieved 13 days later, a sustained neutro-
hil count of 0.5  109/L was not reached until
7 days after reinfusion. Platelet independence fol-
owed 12 days later. These children were subsequently
ischarged 57 and 55 days after their initial allogeneic
ransplantations.
osttransplantation Observations
Posttransplantation CD34 assays were per-
ormed in only 2 children. Patient 2 underwent trans-
lantation for a form of MIOP that showed greatly
ncreased numbers of osteoclasts on biopsy from a 1
ntigen–mismatched sibling donor. The PB CD34
ell count was 91.4  107/L before transplantation. A
ustained neutrophil count of 0.5  109 was achieved
y day 26, and CD34 cell counts decreased to 1 
03/mL on day 14 and 2.3  103/mL on day 28.
atient 6 was also studied at 4 and 6 months after trans-
lantation, and the CD34 cell count was 4  103/mL
nd 1  103/mL, respectively.
ISCUSSION
It has long been recognized that children with
IOP have a leukoerythroblastic blood picture and
hat myeloid colonies can be freely grown from pe-
ipheral blood mononuclear cells; indeed, this growth
an be so exuberant as to impair interpretation of
ixed lymphocyte reactions performed for graft-ver-
us-host disease prediction unless recipient MNCs are
rst isolated [16]. This is assumed to be due to dis-
lacement of hemopoiesis to the extramedullary com-
artment and is reminiscent of primary myeloﬁbrosis.
n the latter, PB has been shown to contain 25- to
5-fold more CFU-GM precursors than normal PB
nd 13-fold more BFU-E [17-19].
We have been concerned that patients undergoing
lternative donor SCT for MIOP are required to
ndergo transplantation without previously storing
utologous cells, even though graft failure is common
n this patient population [5]. This is particularly true
here T-cell depletion has been used, especially with
ampath antibodies and after haploidentical trans-
lantations. Although further infusions from the orig-
nal, or a second, allogeneic donor can be used in this
ircumstance, autologous rescue may be preferred by
ome families or may be dictated by clinical circum-
tance. Examples of the latter include situations in
hich severe infection occurs (eg, patient 1) or addi-
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1ional stem cells cannot be sourced (eg, cord blood
ransplants).
We reasoned that high precursor frequencies may
e reﬂected by high spontaneous PBSC counts and
hat these would facilitate easy collection of autolo-
ous harvests capable of accelerating return to trans-
usion independence if reinfused after rejection. This
tudy has shown that the vast majority of patients with
evere MIOP have extremely high numbers of circu-
ating PBSCs (typically in the range of 1%-5%) and
hat these have progenitor potential comparable to
hat of normal donor BM. However, they behave like
BSC or cord blood samples in their inability to
enerate CFU-F, and this implies a lack of signiﬁcant
esenchymal stem cells. One proposed mechanism of
his increase in circulating undifferentiated cells may
e differences in the presence of cytokines stimulatory
o these cells in patients with severe OP. However,
hen serum from a patient with OP and a high pro-
ortion of circulating CD34 cells was added to an in
itro colony-forming assay, no change was observed in
he number of colonies (data not shown). The density
f PBSC is such that very small exchange transfusions
calculated range, 8.3-83.7 mL) may be required to
btain a desirable number of cells for reinfusion (in this
tudy set, the goal was 2  106 CD34 cells per kilo-
ram). Arguably, it may be wise to take multiples of this
gure if it can be done easily, to maximize the reconsti-
ution potential of the harvest. We therefore took vol-
mes up to 300 mL in children ranging in weight from
.8 to 12.1 kg, all without clinical incident and in a
rocedure lasting 15 to 45 minutes. Exchange transfu-
ion was preferred over repeated blood draws to avoid
ultiple cryopreservation procedures, although invari-
bly the concentration of CD34 cells will decrease
uring a single exchange procedure.
The return of autologous PBSCs in 2 patients
llowed transfusion independence and successful dis-
harge. Patient 1 is alive and well 4 years later, al-
hough she continues to have low platelet counts in
he range of 19 to 55  109/L (secondary to the
evelopment of antiplatelet antibodies that caused her
o be platelet refractory during transplantation). Pa-
ient 4 subsequently underwent a second elective
ransplantation, but this was complicated by fatal pul-
onary arterial hypertension, which is now recog-
ized as a common complication of SCT for MIOP
20,21]. It cannot be known to what extent the autol-
gous reinfusions speeded count recovery, although
e were encouraged that both patients recovered un-
ventfully from their rejection and infection episodes.
f particular note, patient 1 had undergone hap-
oidentical transplantation complicated by respiratory
bstruction requiring emergency tracheostomy; cyto-
egalovirus; and adenovirus infections. Considering
he ease of performing these collections, we advocate
hat this should become standard practice for any
20hild undergoing alternative donor transplantation for
IOP.
There are 2 potential added values to the collec-
ion of PB in OP children. The ﬁrst provocative ob-
ervation is that the 2 children with the lowest CD34
ell counts had atypical clinical forms of OP; if con-
rmed in larger studies, this may allow better identi-
cation of such patients. We also will follow up future
atients to see how CD34 cell counts vary with time
n untransplanted disease. The second has come with
he development of techniques for growing osteoclasts
rom PB or BM in vitro on animal bone slices in the
resence of macrophage colony-stimulating factor and
eceptor activator nuclear factor-B ligand [10]. Os-
eoclasts can be identiﬁed unequivocally by coexpres-
ion of calcitonin and 	v
3 vitronectin receptors, ca-
hepsin K, and tartrate-resistant acid phosphatase,
hus allowing assessment of their ability to be formed,
eal on to the bone surface, and form resorption pits.
ith this technique, it has been possible to show that
hildren with the less common hypo-osteoclastic vari-
nts of OP will not form osteoclasts in vitro; this
hows that their mechanism of disease is different and
s not due to a lack of intrinsic macrophage colony-
timulating factor or receptor activator nuclear fac-
or-B ligand production [9].
Currently, the molecular mechanisms and genet-
cs of this disease are still unresolved for approxi-
ately one third of affected families [22,23]. For
hese, antenatal diagnosis is still restricted to ultra-
ound or plain radiologic studies late in pregnancy—
nvestigations with a recognized failure rate [24]. The
any animal models of OP [25] and the very variable
henotype (eg, classic, neuronopathic, and intermedi-
te) suggest that a range of genes may be involved.
echanistic in vitro analysis of their osteoclast func-
ion may eventually allow grouping of families with
imilar pathology and, hence, more reﬁned and pro-
uctive searches for the causative genes.
In conclusion, we propose that the collection of
BSCs by drawing sufﬁcient blood or by limited ex-
hange transfusion should be considered for all chil-
ren about to undergo SCT for MIOP from alterna-
ive donors. The procedure is quick and well
olerated, and the autologous harvest obtained could
rovide an option not otherwise available should life-
hreatening graft failure or infection occur. We also
uggest that measurement of PB CD34 cells, in con-
unction with bone biopsies and in vitro culture of
steoclasts, may allow valuable insights into the patho-
hysiology of the unclassiﬁed forms of human OP.
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